Table 4. Survival.
| Irinotecan+5- FU/LV (N=56) | Etoposide+5- FU/LV (N=58) | ||
|---|---|---|---|
| Survival parameter | Median time in months (95% CI) | Statistical comparisona Hazard ratio (95% CI) | |
| Progression-free survival | 4.5 (3.4–5.8) | 2.3 (2.0–4.7) | 1.10 (0.75–1.62) |
| P=0.6116 | |||
| Time to treatment failure | 3.6 (2.4–5.1) | 2.2 (1.5–2.9) | 1.15 (0.79–1.67) |
| P=0.4542 | |||
| Overall survival | 10.8 (9.0–13.2) | 8.3 (6.6–11.4) | 1.25 (0.83–1.86) |
| P=0.2818 | |||
5-FU=5-fluorouracil; LV=leucovorin; CI=confidence interval.
a
Hazard ratio >1 favors irinotecan+5-FU/LV; P-value from log-rank test.